Skip to main content

I C U Medical Inc(ICUI-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

ICU Medical, Inc. Announces Time of Third Quarter 2020 Earnings Conference Call

Globe NewsWire - Thu Oct 15, 2020

SAN CLEMENTE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its third quarter 2020 earnings release and conference call.

The Company will release its third quarter 2020 results on Thursday, November 5th, 2020 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, November 5th, 2020. The call can be accessed at (800) 936-9761, conference ID 9959519. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.

About ICU Medical, Inc.

ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells innovative medical products used in infusion therapy and critical care applications. ICU Medical's product portfolio includes IV smart pumps, sets, connectors, closed system transfer devices for hazardous drugs, sterile IV solutions, cardiac monitoring systems, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical, Inc. can be found at www.icumed.com.

CONTACT:

ICU Medical, Inc.
Brian Bonnell, Chief Financial Officer
(949) 366-2183

ICR, Inc.
John Mills, Managing Partner
(646) 277-1254

Source: ICU Medical, Inc.

Primary Logo

Provided Content: Content provided by Globe NewsWire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe